After a tireless campaign by the Cystic Fibrosis Trust and the CF community, England, Wales, Scotland and Northern Ireland now have access to all currently-licensed CF precision medicines: Kalydeco, Orkambi and Symkevi.
We are now focussing our efforts on the latest Vertex precision medicine, the triple combination therapy (known as Trikafta in the United States). Find out where the drug is at in the licensing process, who it could stand to benefit and what we are doing to support the process.
On 30 January 2020, the UK Cystic Fibrosis Medical Association wrote a letter to Matt Hancock, Secretary of State for Health and Social Care, regarding the availability of new treatments for cystic fibrosis in the UK. You can read this letter here.
Read the letter
For the latest news on our Stopping the Clock campaign and other updates in the CF community, sign up to receive our e-newsletter.